Fu et al. found that ALDOA contributes to the activation of the EGFR/MAPK pathway, thereby promoting the expression of cyclin D1 and enhancing the proliferation of NSCLC [50]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.